Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Respir J ; 22(2): 335-41, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12952270

ABSTRACT

Acute respiratory distress syndrome (ARDS) is associated with altered plasma and lung iron chemistry. Iron can promote microbial virulence and catalyse pro-oxidant reactions, thereby contributing to the oxidative stress that characterises the syndrome. Therefore, the expression of ferritin and transferrin receptors (TfR) were sought in the lungs and hearts of rodents treated with lipopolysaccharide (LPS), and measurements of TfR and ferritin protein expression were taken from lung biopsy specimens from patients with ARDS and appropriate controls. TfR messenger ribonucleic acid (mRNA) was significantly upregulated in the lungs and significantly downregulated in the hearts of rats 4 h after LPS. Ferritin mRNA levels (light and heavy chains) remained unaltered. Protein TfR levels were significantly upregulated in lungs and downregulated in hearts 4 h post-LPS. Ferritin protein levels were significantly downregulated in lungs compared to baseline values but were unaltered in hearts. Nonhaem iron levels were increased in lungs and decreased in hearts, and iron-regulatory-protein activity increased in hearts but not lungs. TfR protein levels were significantly increased in lung biopsies from patients with ARDS compared to controls. Transferrin receptors are upregulated in rodent lungs during inflammation but are downregulated in the heart. Transferrin receptor protein levels were significantly increased in the lungs in clinical acute respiratory distress syndrome. These findings have implications for the pathogenesis of acute respiratory distress syndrome, especially in relation to the role of iron as a mediator of oxidative stress.


Subject(s)
Ferritins/metabolism , Lung/metabolism , Myocardium/metabolism , Receptors, Transferrin/metabolism , Respiratory Distress Syndrome/metabolism , Adult , Aged , Animals , Child , Disease Models, Animal , Feedback, Physiological/physiology , Female , Humans , Lipopolysaccharides/adverse effects , Lung/pathology , Male , Middle Aged , Myocardium/pathology , Rats , Rats, Wistar , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/pathology
2.
J Pharmacol Exp Ther ; 299(2): 782-92, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11602695

ABSTRACT

The muscarinic receptor agonist xanomeline was examined and compared with the antipsychotics clozapine and/or haloperidol in the following in vivo rat models: apomorphine-induced disruption of prepulse inhibition (PPI), amphetamine-induced hyperlocomotion, and the conditioned emotional response (CER) test. The effects of xanomeline were also assessed ex vivo on dopamine turnover in the rat medial prefrontal cortex. Under conditions of varying dose and prepulse intensity, xanomeline, like haloperidol, had no effect on PPI. In contrast, the muscarinic receptor antagonist scopolamine and the muscarinic receptor agonist pilocarpine both induced significant dose-dependent deficits in PPI. Haloperidol and xanomeline, but not pilocarpine, dose dependently reversed apomorphine-induced disruption of PPI. Thus, xanomeline induced a clear antipsychotic-like effect in PPI, whereas pilocarpine appeared to induce a psychotomimetic-like effect. Xanomeline attenuated amphetamine-induced hyperactivity at doses that had no effect on spontaneous activity, possibly indicating a separation between attenuation of limbic hyperdopaminergic function and the induction of hypolocomotion. Haloperidol and clozapine also reversed amphetamine-induced hyperlocomotion, but at similar doses to those that reduced spontaneous locomotion. Clozapine, but not haloperidol had an anxiolytic-like effect in the CER test. The effects of xanomeline in the CER test were similar to those of clozapine, although at the anxiolytic dose it tended to disrupt baseline levels of lever pressing. Finally, haloperidol, clozapine, pilocarpine, and xanomeline, all induced an increase in dopamine turnover in medial prefrontal cortex. The antipsychotic-like effects of xanomeline in the animal models used here suggest that it may be a useful treatment for psychosis.


Subject(s)
Antipsychotic Agents/pharmacology , Behavior, Animal/drug effects , Muscarinic Agonists/pharmacology , Pyridines/pharmacology , Thiadiazoles/pharmacology , Amphetamine , Animals , Central Nervous System Stimulants , Conditioning, Psychological/drug effects , Conflict, Psychological , Dopamine/metabolism , Emotions/drug effects , Hyperkinesis/chemically induced , Hyperkinesis/prevention & control , Male , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Rats , Rats, Sprague-Dawley , Reflex, Startle/drug effects
3.
Neuroscience ; 83(4): 1175-83, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9502256

ABSTRACT

Brain microdialysis was used to study changes in dopamine in the nucleus accumbens and the dorsal striatum during associative learning between two neutral stimuli, flashing light and tone, presented on a paired schedule during stage 1 of a sensory preconditioning paradigm. The tone was subsequently paired with mild footshock using standard aversive conditioning procedures and the formation of a conditioned association between the flashing light and the tone in stage 1 was assessed by measuring the ability of the flashing light to elicit the same conditioned response as the tone when presented at test. The first experiment used behavioural monitoring only, to establish stimulus parameters for subsequent microdialysis experiments. Animals receiving paired presentation of the light and tone in stage 1 showed a conditioned suppression of licking to the light as well as to the tone, indicating that associative learning between the flashing light and the tone had occurred during stage 1, whilst in a separate group of animals given the same stimuli over the same time period but on an explicitly non-paired schedule, the conditioned emotional response was seen to the tone, but not to the light, showing that no association had been formed between the two stimuli during stage 1. In dialysis experiments using the same procedure, we measured a two-fold rise in dopamine in the nucleus accumbens during paired presentation of flashing light and tone, but not during non-paired presentation of the two stimuli. On subsequent test presentation of the two stimuli, we saw increases in accumbal dopamine on presentation of the tone in both groups, reflecting the formation of an association with the footshock in both. However the flashing light elicited an increase in dopamine only in the group which had received paired presentation at stage 1. Thus accumbal dopamine release at test is correlated to the ability of the stimulus to evoke a conditioned response measured behaviourally. Hypotheses of the behavioural function of the mesolimbic dopamine system centre on its role in mediating the effects of biological reinforcers, both rewarding and aversive, conditioned and unconditioned. The present results, showing increases in extracellular dopamine in the nucleus accumbens when an association is formed between two stimuli of which neither is a biological reinforcer nor, prior to formation of the association, affects dopamine levels, suggest a role for accumbal dopamine in the modulation of associative learning in general, not only that involving reinforcement.


Subject(s)
Association Learning/physiology , Avoidance Learning/physiology , Corpus Striatum/physiology , Dopamine/metabolism , Nucleus Accumbens/physiology , 3,4-Dihydroxyphenylacetic Acid/metabolism , Acoustic Stimulation , Animals , Chromatography, High Pressure Liquid , Conditioning, Operant , Electroshock , Extracellular Space/metabolism , Homovanillic Acid/metabolism , Hydroxyindoleacetic Acid/metabolism , Male , Microdialysis , Photic Stimulation , Rats , Rats, Sprague-Dawley
4.
Manag Care Q ; 5(1): 25-9, 1997.
Article in English | MEDLINE | ID: mdl-10164646

ABSTRACT

In this article, a health care marketing executive takes an opposing view: That the consumer will not only continue to exercise choice but also, at annual renewal time, veto power. In part, that is because the consumers are feeling the rising cost of health care much more directly than in the past, through ever-higher premiums, deductibles and copayments. As they assumed more of the burden of medical care delivery, consumers are becoming more knowledgeable about and discriminating toward the health care system and provider plans they are offered. They understand--as does their employer--that no longer are all health care plans alike or at parity with each other. The consumer is also demanding greater access to freedom of provider choice, quality of health care coverage.


Subject(s)
Competitive Medical Plans/economics , Consumer Behavior , Marketing of Health Services/methods , Choice Behavior , Economic Competition , Health Benefit Plans, Employee , Hospital-Physician Joint Ventures , Humans , Marketing of Health Services/organization & administration , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...